Geneos Therapeutics Announces Positive Phase 1/2 Data for GT-30 Trial of Personalized Therapeutic Cancer Vaccine
Trial has met primary endpoints of safety and immunogenicity and secondary endpoint for efficacy based on response rate
Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Philadelphia, PA – March 6, 2024 – Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced the upcoming presentation of two posters sharing new clinical data from its Phase 1b/2a GT-30 study of GNOS-PV02, a personalized neoantigen DNA vaccine, in patients with advanced hepatocellular carcinoma, … Read more
Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million
Proceeds Will Fund Completion of GT-30 Trial of Personalized Therapeutic Cancer Vaccine in Liver Cancer
Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response, or, Secondary Resectability in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer
By RECIST1.1, Three Complete Responses and Seven Durable Partial Responses Achieved to Date–
Geneos Therapeutics Nominated for 2023 Prix Galien USA Startup Award
Nomination Recognizes Progress and Promise of Geneos’ Personalized Therapeutic Cancer Vaccines
Geneos Therapeutics Secures $5 Million in Series A3 Financing
Proceeds to Fund Expansion of Phase 1b/2a Trial of Personalized Therapeutic Cancer Vaccine in Liver Cancer
Geneos Therapeutics Announces Another Complete Response in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer
To Date, Four Patients Are Now Cancer Free Out of 23 Evaluable
Geneos Therapeutics Announces Positive Clinical Data for Personalized Therapeutic Cancer Vaccines in Ongoing Liver Cancer Trial
Overall Response Rate 30.4 Percent in 23 Evaluable Patients Including Two Complete Responses and a Third Cancer-Free Patient
Geneos to Highlight Clinical and Supportive Pharmacodynamic Data From Personalized Therapeutic Cancer Vaccine Phase 1b/2a Clinical Trial at SITC Conference
Encouraging Safety and Efficacy Data from Ongoing GT-30 Study in Second-Line HCC
Geneos Therapeutics Secures $17 Million in Series A2 Financing to Advance Personalized Cancer Immunotherapy Platform
Geneos expands its Phase Ib/IIa clinical trial in lead indication for treating patients with advanced hepatocellular carcinoma